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Maryam Pourhajibagher1 & Abbas Bahador2,3* 
This study aimed to focus on the simultaneous use of antimicrobial photodynamic therapy (aPDT) and 
sonodynamic antimicrobial chemotherapy (SACT), which is called photo‑sonodynamic antimicrobial 
chemotherapy (PSACT) to attenuate the virulence of Aggregatibacter actinomycetemcomitans. 
Following the synthesis of Curcumin‑decorated nanophytosomes (Cur‑NPhs) as a novel photo‑
sonosensitizer, its particle size, polydispersity, ζ‑potential surface morphology, physical stability, 
drug release, and entrapment efficiency were determined. In the Cur‑NPhs‑PSACT, the antimicrobial 
activities of Cur‑NPhs against A. actinomycetemcomitans were investigated using cell viability, 
biofilm killing/degradation, metabolic activity, expression of quorum‑sensing‑associated qseB and 
qseC genes, and biofilm‑associated rcpA gene under blue laser irradiation plus ultrasonic waves. 
Characterization tests showed the presence of a sphere‑shaped vesicle and the self‑closed structure 
of Cur‑NPhs, resulting in a high drug‑loading content and encapsulation efficiency. However, the 
antimicrobial effect of Cur‑NPhs‑PSACT was dose‑dependent, PSACT using the high concentrations 
of Cur‑NPhs (50 ×  10–4 g/L) showed significant reductions (P < 0.05) in cell viability (13.6  log10 CFU/
mL), biofilm killing/degradation (65%), metabolic activity (89.6%,), and mRNA levels of virulence 
determinant genes (qseB; 9.8‑fold, qseC; 10.2‑fold, and recA; 10.2‑fold). This study concludes that the 
Cur‑NPhs‑PSACT had antimicrobial activities against A. actinomycetemcomitans by downregulating 
the expression of virulence genes, and may attenuate this bacterium that decreases periodontal 
disease severity in patients.
Periodontal disease is a collective form of the inflammatory disorder that is induced by oral microorganisms, 
dental plaque, or dental biofilm. According to the latest Portuguese Oral National Health Survey (PONHS), the 
prevalence of periodontitis was 10.8% and 15.3% in adults and the elderly,  respectively1. Several factors that 
increase the risk of periodontal diseases are divided into two groups; 1. Modifiable risk factors such as smoking, 
poor oral hygiene, hormonal changes in females, diabetes mellitus, medications, and stress, 2. Non-modifiable 
risk factors including age and  hereditary2. In addition, microbial pathogens are one of the most common causa-
tive agents of periodontal  disease3.
Aggregatibacter actinomycetemcomitans is one of the main causes of periodontal disease in juveniles and 
 adolescents4. The pathology and etiology of periodontal disease have demonstrated several virulence factors 
such as lipopolysaccharide (LPS), fimbriae, and enzymes can trigger inflammation in periodontal tissues caused 
by A. actinomycetemcomitans5.
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The success of periodontitis treatment depends on eliminating the bacterial load of periodontal pockets to 
restore biological compatibility of periodontally diseased root  surfaces6. The treatment of periodontitis is chal-
lenging and routine mechanical or non-surgical periodontal treatments do not diminish effectively the load of 
the microbial strains. On the other hand, the over-use of systemic and local antibiotics has been the main reason 
for the emergence of drug-resistant  bacteria7. Nevertheless, the application of the alternative approaches for the 
removal of periopathogens from periodontal pockets is highly essential. Therefore, the development of a new 
antimicrobial approach with fewer complications is necessary.
Antimicrobial photodynamic therapy (aPDT) and sonodynamic antimicrobial chemotherapy (SACT) as the 
non-invasive therapeutic modalities are the new antimicrobial strategies to improve periodontal  treatment8. 
SACT is analogous to aPDT, except that drug activation is achieved through ultrasound instead of visible light. As 
well, photosensitizer as a photosensitizing agent in aPDT is replaced by sonosensitizer as a sonosensitizing agent 
in SACT 9. The antimicrobial effects of aPDT and SACT depend on the production of cytotoxic reactive oxygen 
species (ROS) including singlet oxygen (1O2), hydroxyl radicals (·OH), peroxyl radical (ROO·), and superoxide 
 (O2−) ions causing damage to the cellular and molecular structures of  microorganisms10.
In the present study, for the first time, we aim to examine the antimicrobial effects of the simultaneous use 
of aPDT and SACT, which called photo-sonodynamic antimicrobial chemotherapy (PSACT) using Curcumin-
decorated nanophytosomes (Cur-NPhs) as the photo-sonosensitizer on the regulation of qseB and qseC genes 
expression in A. actinomycetemcomitans. After confirmation of Cur-NPhs synthesis, we examined the effects of 
Cur-NPhs-mediated PSACT on cell viability, biofilm degradation, metabolic activity, and qseB and qseC genes 
expression.
By revealing the interaction of suppression of metabolic activities during treatments with suppression of rcpA 
expression among A. actinomycetemcomitans, we attempt to explain, at least in part, the suppression of rcpA 
expression is likely a byproduct of the general suppression of metabolic activities, and the Cur-NPhs-mediated 
PSACT targeted specifically the bacterial biofilm structure. Our findings might provide additional options for 
the management of periodontitis and/or pri-implantitis, either as direct treatment strategies or adjuncts to 
routine methods.
Results
Confirmation of synthesized Cur‑NPhs. As shown in Fig.  1a, the size of the Cur-NPhs was 
156.42 ± 2.06 nm and the polydispersity index was 0.34 ± 0.02. The presence of a sphere-shaped vesicle and the 
self-closed structure was indicated in the TEM of the Cur-NPhs complex (Fig. 1b). It was observed that the aver-
Figure 1.  Characterization of synthesized Cur-NPhs. (a) Representative scanning electron micrograph (scale 
bar represents 10 μm). (b) Representative transmission electron micrograph (scale bar represents 30 nm). (c) 
Average particle size. (d) ζ-potential value.
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age particle size and the ζ-potential value were 86.3 ± 2.08 nm and − 34.7 ± 1.3 mV, respectively, which indicate 
good stability (Fig. 1c,d).
High EE is the main factor for the choice of a specific carrier and the encapsulation approach. According to 
the results, the EE percentage of the Cur in Cur-NPhs was 83.56 ± 0.5%.
In vitro drug release. The release profile showed the release of Cur occurred in a biphasic process in which 
a rapid initial burst of about 12% within the first hour followed by sustained drug release of about 74% in 4 h 
(Fig. 2). The drug entrapped on the surface of the phytosomes might be the reason for the observed initial burst 
release.
Physical stability of Cur‑NPhs. Cur-NPhs stability was measured by particle size over 2 weeks at 4 °C and 
37 °C, which showed no significant variation between day 0 and day 14 (P > 0.05; Fig. 3). The results showed no 
significant changes in polydispersity index and ζ-potential of Cur-NPs during 2 weeks.
Also, the effects of different pH treatments on the RR of Cur-NPs were shown in Fig. 4. During the 24 and 
48 h storage period, Cur-NPhs were more stable under acidic conditions with RR more than 90%, whiles RR of 
Cur-NPhs decreased to 55% at neutral and alkaline conditions. Meanwhile, no significant changes were achieved 
in RR of Cur-NPhs after 48 h of storage (P > 0.05). It is therefore concluded that Cur-NPs did not undergo deg-
radation on storage.
Cytotoxicity effects of treatment groups on A. actinomycetemcomitans viability. A dose-
dependent decrease was observed in  log10 CFU/mL of A. actinomycetemcomitans (Fig. 5). The  log10 CFU/mL 
reduction was increased to 3.3 ± 0.06, 5.1 ± 0.08, and 6.8 ± 0.05, after treatment with 10, 25, and 50 ×  10–4 g/L Cur-
NPhs, respectively (P < 0.05). As shown in Fig. 5, cell viability significantly decreased in treated A. actinomycet‑
emcomitans with aPDT and SACT using different concentrations of Cur-NPhs compared with the control group 
(P < 0.05). The results indicated that 50 ×  10–4 g/L Cur-NPhs plus 2 min blue laser irradiation in aPDT group and 
50 ×  10–4 g/L Cur-NPhs plus ultrasonic waves with the intensity of 1.56 W/cm2 in SACT group could effectively 
decrease 10.7 ± 0.05  log10 CFU/mL and 11.2 ± 0.03  log10 CFU/mL of microbial cells, respectively (P < 0.05). Inter-
estingly, PSACT was able to reduce the survival rate of bacteria more than the other groups compared to the 
control group (P < 0.05), so that a 13.6 ± 0.08  log10 CFU/mL reduction was observed in 50 ×  10–4 g/L Cur-NPhs-
PSACT-treated cells (Fig. 5).
According to the data obtained in the present study, there was no significant difference in the rate of A. 
actinomycetemcomitans viability following NPhs, NPhs-mediated aPDT-, SACT-, and PSACT-treatment, blue 
laser irradiation at a wavelength of 450 ± 5 nm for 2 min, as well as, ultrasonic waves with the intensity of 2 W/
cm2 for 2 min at a frequency of 1 MHz (P > 0.05).
Anti‑biofilm potency of treatment groups against A. actinomycetemcomitans. The results of 
the CV assay showed that aPDT, SACT, and PSACT with different concentrations of Cur-NPhs decreased the 
biofilm forms of A. actinomycetemcomitans compared to that of untreated biofilm (P < 0.05; Fig. 6). According to 
the results, degradation of A. actinomycetemcomitans biofilms was dose-dependent. PSACT using 50 ×  10–4 g/L 
Cur-NPhs plus ultrasound waves with the intensity of 1.56 W/cm2 was the most effective biofilm degradation 
against A. actinomycetemcomitans (65% biofilm killing; P < 0.05). In contrast, there was no considerable degra-
dation in biofilms of A. actinomycetemcomitans exposed to the NPhs, Cur-NPhs, blue laser irradiation, ultra-
sonic waves alone, NPhs-mediated aPDT-, SACT-, and PSACT-treatment (P > 0.05).
Determination of A. actinomycetemcomitans metabolic activity following treatment 
groups. Although considerable reduction of A. actinomycetemcomitans metabolic activity was observed 
Figure 2.  Profile of Cur release from Cur-NPhs.
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upon treatment with Cur-NPs-aPDT and Cur-NPs-SACT, therapy employing Cur-NPs-PSACT generated a sig-
nificant reduction of metabolic activity more than other groups (Fig. 7; P < 0.05). There was a more significant 
reduction of metabolic activity following Cur-NPhs-PSACT at the concentrations of 10, 25, and 50 ×  10–4 g/L 
to 49.3%, 69.2%, and 89.6%, respectively (all P < 0.05; Fig. 7). In contrast, no significant changes were observed 
in metabolic activity of A. actinomycetemcomitans after exposure with blue laser irradiation, ultrasonic waves, 
and different concentrations of NPs and Cur-NPhs alone (P > 0.05), except 50 ×  10–4 g/L Cur-NPhs (P < 0.05). 
Also, there was no significant effect in metabolic activity of A. actinomycetemcomitans following NPhs-mediated 
aPDT-, SACT-, and PSACT-treatment (P > 0.0.5).
Monitoring of quorum‑sensing (QS)‑associated qseB and qseC genes expression. The agarose 
gels of the amplified product showed the single bands corresponding to the predicted amplicon length. The 
amplification of qseB, qseC, and 16S rRNA yielded no false-positive and unspecific bands in test samples (Fig. 8). 
Figure 3.  Particle size, polydispersity index, and ζ-potential of Cur-NPhs in different conditions; (a) at 4 °C, (b) 
at 37 °C.
Figure 4.  Retention rate percentage of Cur-NPhs at different pH; (a) during 24 h and (b) 48 h storage period.
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As shown in Fig. 8, dissociation melting curves of qseB, qseC, and 16S rRNA amplicons with a single peak dem-
onstrates the specificity of the designed primer pairs.
The transcript levels of the biofilm-associated genes, qseB and qseC, were measured by performing qRT-
PCR experiments. This study indicated that there was a dose-dependent manner effect of the treatment on the 
expression levels of qseB and qseC. The results showed that the expression levels of qseB were downregulated 
Figure 5.  Cell viability of A. actinomycetemcomitans following different treatments. Significant differences 
according to the control, *P < 0.05.
Figure 6.  Biofilm degradation ability of A. actinomycetemcomitans following different treatments. Significant 
differences according to the control, *P < 0.05.
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4.2-, 6.5-, and 9.8-fold in treated A. actinomycetemcomitans by PSACT using 10, 25, and 50 ×  10–4 g/L Cur-NPhs, 
respectively (Fig. 9; P < 0.05). Corresponding values in qseC were 4.7-, 7.2-, and 10.2-fold, respectively (P < 0.05).
As shown in Fig. 9, there were the significant 2.5-, 4.9-, and 6.3-fold downregulation of qseB and 3.1-, 5.4-, 
and 7.8-fold downregulation of qseC, in response to 10, 25, and 50 ×  10–4 g/L increased concentrations of Cur-
NPhs during aPDT, respectively (P < 0.05). Also, the transcript levels of qseB were downregulated 3.1-, 5.2-, and 
7.3-fold, respectively, in treated A. actinomycetemcomitans by SACT using10, 25, and 50 ×  10–4 g/L Cur-NPhs 
compared with those in the transcript levels of qseC that were 3.6-, 6.0-, and 8.3-fold, respectively (P < 0.05). 
According to the data obtained in the present study, there was no significant difference in the rate of transcript 
levels between the two genes in treated A. actinomycetemcomitans with aPDT and SACT (P > 0.05). As shown in 
Fig. 9, there was no significant changes in gene expression of qseB and qseC following NPhs-mediated aPDT-, 
SACT-, and PSACT-treatment (P > 0.0.5).
Monitoring of biofilm‑associated rcpA gene expression. Significant reductions of rcpA were 
observed at 10, 25, and 50 ×  10–4 g/L of Cur-NPhs-aPDT-, SACT-, and PSACT-treated A. actinomycetemcomitans 
(4.4-, 5.2-, and 9.7-fold, respectively). No significant change of rcpA mRNA expression was observed in treated 
Figure 7.  Metabolic activity of A. actinomycetemcomitans following different treatments. Significant differences 
according to the control, *P < 0.05.
Figure 8.  Specificity of the designed primers; a. A 2% agarose gel electrophoresis for detection of qseB, qseC, 
and 16S rRNA. L ladder 100 bp, i: qseB, ii: qseC, iii: 16S rRNA. b. Melting curve, i: qseB, ii: qseC, iii: 16S rRNA.
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groups using NPhs-aPDT, NPhs-SACT, and NPhs-PSACT at the concentrations of 10, 25, and 50 ×  10–4 g/L (all 
P > 0.05; Fig. 10).
Discussion
PSACT can be defined as the promising approach for eradication of microbial cells through the interaction of 
photo-sonosensitizer as a non-toxic photo-sonosensitizing agent with visible light at specific wavelength and 
ultrasonic waves with specific intensity. PSACT minimizes the side effects, maximizes the responses on-target, 
and can be focused deeply within the target site to a single discrete point in three  dimensions11. After the activa-
tion of photo-sonosensitizer with the appropriate wavelength of light, electrons are transferred from a low to 
a higher level of energy which is called the triplet state that can undergo two pathways: transfer directly to the 
neighboring molecule or cell membrane (type-1 reaction) to form a radical anion which reacts with oxygen to 
produce ROS; or transfer its energy directly to molecular oxygen (type-2 reaction) to produce excited-state singlet 
 oxygen12–14. In addition, the relatively low-intensity ultrasound excites the photo-sonosensitizer at the target site, 
which leads to microbubble formation through the acoustic cavitation process resulting in the generation of ROS.
The characteristics of the ideal photo-sonosensitizer have been discussed  previously15. Briefly, they should 
be chemical purity non-toxic, absorb the light in the red or far-red wavelengths, eliminate rapidly from normal 
tissue, be cost-effective and easily available, and generate a large number of cytotoxic products. Based on the 
literature, the photosensitizers used in the treatment of periodontitis included methylene blue (MB), indocyanine 
green (ICG), phenothiazine chloride, toluidine blue (TBO), and  Cur16–22.
Curcumin longa, derived from the turmeric rhizomes (Curcuma longa L.), is well known for its wide range 
of pharmacological  properties23. The bioavailability limitations of Cur such as its hydrophobicity, low solubility, 
Figure 9.  Gene expression levels of qseB and qseC following different treatments. Significant differences 
according to the control, *P < 0.05.
Figure 10.  Gene expression levels of rcpA following different treatments. Significant differences according to 
the control, *P < 0.05.
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instability, poor absorption, rapid metabolism, and fast systemic removal have led to ongoing attempts for 
developing a new formulation to enhance its solubility, bioavailability, and therapeutic  activities24. Evidence 
from several studies has indicated that phytosomes markedly improve the bioavailability and pharmacokinetics 
of  Cur24,25. As recently reported by Purpura et al.26, phytosomes significantly improve the relative human bio-
availability of Cur by 19.2-fold for Cur alone. It has been observed that Cur is directly bound to the polar head of 
phosphatidylcholine in phytosomes and the covalent bonds between phosphatidylcholine and the phytochemi-
cal cargo (i.e., Cur) are the main factor in stability profile of phytosomes compared with many other delivery 
 systems27. Although there are several studies that investigate the efficacy of phytosomal Cur in the treatment of 
cancer, diabetes, and inflammatory  diseases28–32, no study has hitherto assessed the antimicrobial properties of 
Cur-decorated NPhs especially during PSACT against periopathogenic bacteria.
In the current study, Cur-NPhs alone were able to reduce the planktonic A. actinomycetemcomitans counts 
significantly but had no inhibitory effect on biofilm growth. The observation of resistance to the Cur-NPhs when 
A. actinomycetemcomitans was grown in biofilms, suggests that biofilm formation is one of the critical viru-
lence factors for this species, which permits A. actinomycetemcomitans to establish persistent periodontitis and 
peri-implantitis. Biofilm production by A. actinomycetemcomitans and its role in oral infections remain poorly 
studied. It has been revealed that the resistance of biofilms to antimicrobial agents is increased 10–1000 times 
compared with what is normally seen with planktonic bacteria. In fact, when microbial cells exist in a biofilm, 
may be more resistant to antimicrobial agents because the microorganisms are protected against the action of the 
agents, with the biofilm impairing the entry of agents by acting as a barrier for diffusion. The biofilm matrix also 
can react with or adsorb the antimicrobial agents, thereby reducing the number of available agents to interact 
with microbial cells in the biofilm structure. In addition, microbial cells in biofilm structure have reduced growth 
rates and metabolic activity. Another possibility that microbial cells in the biofilm are tolerant to antimicrobial 
agents is conjugation among biofilm cells. This exchange of genes is important for the acquisition of resistance 
genes and genetic diversity of bacterial communities and favors the exchange of genes that can involve in more 
antimicrobial  resistance33,34.
The results of characterization of synthesized Cur-NPhs as the photo-sonosensitizer in the current study are 
consistent with a recent report in which strong interaction between Cur and phosphatidylcholine leads to the 
stability of  phytosomes26. The significant reduction of  log10 CFU/mL in A. actinomycetemcomitans (13.6  log10 
CFU/mL reduction) following PSACT using the high concentrations of Cur-NPhs (50 ×  10–4 g/L) combined 
with the blue laser irradiation at a wavelength of 450 ± 5 nm plus ultrasonic waves with the intensity of 1.56 W/
cm2 at a frequency of 1 MHz for 2 min showed that Cur-NPhs-PSACT had an antibacterial effect. The results of 
this study revealed the activation of Cur-NPhs using both blue laser irradiation and ultrasonic waves enhanced 
the antimicrobial activity of Cur-NPhs which could be due to increased ROS and singlet oxygen. So, Cur-NPhs-
PSACT had higher antibacterial activity than Cur-NPhs-aPDT and Cur-NPhs-SACT against A. actinomycetem‑
comitans. According to our results, activated NPhs by blue laser irradiation, ultrasonic waves, and both of them 
in NPhs-aPDT, NPs-SACT, and NPhs-PSACT treatment had no contribution to the observed antimicrobial 
effects. Notably, our finding that Cur-NPhs-aPDT had an antibacterial effect against A. actinomycetemcomitans 
is similar to previous reports, which show the antibacterial effect of Cur-aPDT35.
As previously mentioned, biofilm structures are the protected niches for A. actinomycetemcomitans against 
host defense, hostile environments conditions, and antimicrobial  treatment36,37. Nevertheless, some antimi-
crobial molecules can penetrate throughout the biofilm matrix and lead to biofilm degradation. Our findings 
are consistent with recent studies that show aPDT using Cur as a photosensitizer is efficient in the reduction 
of microbial  biofilms38. As the results of this study showed, PSACT using 50 ×  10–4 g/L Cur-NPhs had the most 
effective anti-biofilm activity against A. actinomycetemcomitans and could degrade the biofilm cells up to 65%. 
In addition, the results showed that the reduction of A. actinomycetemcomitans metabolic activity was dose-
dependent. There was a more significant reduction of metabolic activity following Cur-NPhs-mediated PSACT 
at the concentrations of 50 ×  10–4 g/L about 90.0%. Additionally, aPDT and SACT with 50 ×  10–4 g/L Cur-NPhs 
could decrease the metabolic activity to 70% and 78%, respectively. The finding indicated the antimetabolite 
activity of PSAT was more than aPDT and SACT.
The results regarding the reduction of metabolic activity of A. actinomycetemcomitans during aPDT treat-
ment, corroborate with the results found in the literature for this and another  pathogen35,39,40. Ari et al.40 studied 
the effects of bystander responses following aPDT using Cur as a photosensitizer on A. actinomycetemcomitans 
biofilm growth. Their results showed that bacterial metabolic activity significantly decreased by 42.6% after 
exposure to bystander effects induced by Cur-aPDT treated whole bacterial cell suspension. In the study reported 
by Pourhajibagher et al.35, the metabolic activity of treated A. actinomycetemcomitans by nano-chitosan encap-
sulated ICG-mediated aPDT was assessed. Based on their results, a statistically significant reduction (48%) was 
observed in the metabolic activity of A. actinomycetemcomitans.
The QseBC two-component systems are characterized as the global regulators of virulence. QseBC is asso-
ciated with QS and essential for A. actinomycetemcomitans to adapt and respond to various environmental 
 stimuli41. As Novak et al.42 reported, QseBC contributes to the regulation of colonization, biofilm formation, 
and expression of virulence genes in A. actinomycetemcomitans. Based on the QseBC signaling cascade of A. 
actinomycetemcomitans, the expression of qseBC in A. actinomycetemcomitans is induced by exogenous autoin-
ducer-2 (AI-2), which may occur via the motility QS  regulator43. Also, the expression of rcpA has been linked to 
biofilm production. RcpA protein has been demonstrated to be involved in outer membrane channel formation 
that allows for the secretion of the assembled fimbriae to the microbial cell surface. Fimbriae in this species are 
responsible for biofilm formation which ultimately lead to increased antimicrobial  resistance44.
Weigel et al.43 reported the functional outcomes of A. actinomycetemcomitans QseBC have been defined 
as influencing biofilm growth and virulence. Also, the findings of Novak et al.42 study indicated that qseBC is 
require for stimulation of biofilm formation of A. actinomycetemcomitans in an animal model of periodontitis. 
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In this study, both qseB and qseC genes were significantly downregulated after treatment with Cur-NPhs-aPDT-, 
SACT-, and PSACT-treated A. actinomycetemcomitans Cur-NPhs-mediated PSACT compared to the other con-
trol groups. Interestingly, the downregulation of qseB and qseC on treated A. actinomycetemcomitans were dose-
dependent and may be involved in the attenuation of A. actinomycetemcomitans QS.
Moreover, in the current study, after exposing the biofilm of A. actinomycetemcomitans strains to Cur-NPhs-
PSACT, rcpA gene expression was potentially downregulated in a dose-dependent manner which may be the 
result of the accumulation of Cur-NPhs in the biofilm environment. Since the rcpA gene plays an important 
role in biofilm formation in A. actinomycetemcomitans, the expression inhibition of this gene following Cur-
NPhs-PSACT treatment may cause to decrease bacterial adhesion, biofilm formation, and its pathogenicity. 
Various recent reports have shown that aPDT can overcome bacterial biofilm formation through affecting rcpA 
gene expression in A. actinomycetemcomitans6,35. Pourhajibagher et al.35 investigated the efficacy of Cur-aPDT 
as an alternative antimicrobial approach against A. actinomycetemcomitans. Their results indicated aPDT with 
Cur leads to significantly decreased A. actinomycetemcomitans cell survival and reduced the expression of the 
rcpA gene by approximately 8.5-fold. In another study, the outcome of the expression level of A. actinomycetem‑
comitans rcpA gene following treatment by ICG-aPDT was investigated. The results showed that ICG-mediated 
aPDT using 125 μg/mL ICG at the fluency of 15.6 J/cm2 of diode laser irradiation could significantly reduce 
the expression of A. actinomycetemcomitans rcpA gene approximately  sixfold6. According to the results of the 
current study, no change in rcpA, qseB, and qseC mRNA expressions in either of the NPhs and NPhs-treated 
groups during aPDT-, SACT-, and PSACT-treatment suggests these treatments have no effect on expressions of 
test genes and therefore on biofilm production in A. actinomycetemcomitans.
Conclusion
This study concludes that the Cur-NPhs-PSACT could reduce the cell viability, metabolic activity, and biofilm 
growth in A. actinomycetemcomitans by downregulating the expression of rcpA, qseB, and qseC genes, and may 
attenuate pathogens that decrease disease severity in patients with periodontitis and peri-implantitis. Our find-
ings warrant detailed examination of the interactions between the Cur-NPhs-PSACT as an adjunctive therapy and 
pathogenicity of the main periodontal pathogens toward efforts to successful treatment of periodontal infections.
Materials and methods
Materials. Cur and phosphatidylcholine were purchased from Sigma-Aldrich, Steinheim, Germany. Dichlo-
romethane was obtained from Merck, Darmstadt, Germany. Brain heart infusion (BHI) agar and BHI broth 
were purchased from Conda, Torrejon de Ardoz, Spain. Yeast extract, hemin, and menadione were obtained 
from Merck, Darmstadt, Germany. Phosphate buffered saline (PBS), crystal violet (CV), and acetic acid were 
purchased from Sigma-Aldrich, Steinheim, Germany. GeneAll Hybrid-R RNA purification kit was purchased 
from GeneAll Biotechnology Co., Korea. RNase-free DNase I and Revert Aid First Strand cDNA Synthesis Kits 
were purchased from Thermo Fisher Scientific, US. SYBR Green master mix was obtained from Takara, Kyoto, 
Japan. Cell Proliferation Kit II (XTT) was obtained from Sigma-Aldrich, Steinheim, Germany. Ethanol and other 
reagents were all of the analytical grade.
Preparation of Cur‑decorated NPhs. The NPhs preparation was done by de-hydration and re-hydration 
technique of Abdul Azeez et al.45 with minor modifications. Briefly, 0.2 g of phosphatidylcholine was dissolved 
in 20 mL of dichloromethane as an organic solvent and stored for 2 h. The dichloromethane was then removed 
under a reduced pressure and temperature using a rotary vacuum evaporator. A thin layer containing phytosome 
would be formed at the bottom of the flask. After that, the thin layer of phytosome is re-hydrated with distilled 
water to form micelles that are then probe sonicated to achieve NPhs.
Cur-NPhs were prepared according to the method reported recently with slight  modification46. In brief, Cur 
and prepared NPhs in the molar ratio of 1:1 was dissolved in 20 mL of dichloromethane. The mixtures were 
thoroughly mixed at room temperature on a magnetic stirrer and the solvent was evaporated under reduced 
pressure in a rotary evaporator. The obtained thin film was then washed with n-hexane, dried under vacuum, 
hydrated for 2 h, and ultrasonicated to obtain Cur-NPhs. The resultant Cur-NPhs were placed in amber-colored 
glass bottle and stored at room temperature.
Characterization of Cur‑NPhs. Morphology. The surface morphology, size, and shape of prepared Cur-
NPhs were confirmed using a field emission scanning electron microscope (FESEM; Zeiss, Sigma VP, Germany, 
15 kV accelerating voltage). Moreover, the core–shell structure of Cur-NPhs was assessed by transmission elec-
tron microscope (TEM; Zeiss EM10C) with an accelerating voltage of 100 kV.
Measurement of particle size, polydispersity, and ζ‑potential. The Cur-NPhs dispersion was diluted with PBS 
solution prior analysis. Average particle size, polydispersity, and ζ-potential of Cur-NPhs were determined using 
a dynamic light scattering particle size analyzer (Malvern Zetasizer Nano ZS system) at 25 °C with a scattering 
angle of 90°.
Entrapment efficiency (EE). The percentage of Cur incorporated was determined by centrifuging the Cur-NPhs 
at 8000 rpm for 30 min. The supernatant was then obtained to measure the absorbance at 425 nm using a UV–
visible spectrophotometer. The encapsulation efficiency (EE) was determined using the following equation:
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In vitro drug release. The release properties of Cur from Cur-NPhs were obtained as described  earlier47. The 
absorbance of Cur was measured using the UV–visible spectrophotometer at 426 nm. The percentage of released 
Cur was calculated as:
Physical stability of Cur‑NPhs during storage. To evaluate shelf life, Cur-NPhs was stored in the containers at 
4 °C and 37 °C in the dark. Changes in the polydispersity index, particle size, and ζ-potential were investigated 
at different time intervals during storage for 2 weeks. Effects of different pH (pH = 5, 6, 7, 8, 9) on the retention 
rate (RR) of Cur-NPhs was determined after 24 and 48 h of storage. RR of Cur was measured at 425 nm and 
calculated as follows:
Bacterial strain and growth conditions. A. actinomycetemcomitans IR-TUMS/BPG4 (Accession num-
ber in Genbank: KX108928) was grown at 37 °C in a capnophilic condition (3–5%  CO2 and 8–10%  O2) in BHI 
broth supplemented with 0.6% yeast extract and 1 mg/L  menadione48.
Light source. A continuous blue laser (ASHA, Iran) at the wavelength of 450 ± 5 nm with an output intensity 
of 150 mW/cm2, 4.2 V, and 0.34 A was used as a light source. The blue laser was placed approximately 1 mm away 
from the surface of the bacterial suspension.
Ultrasound system. SACT testing was done as described previously with slight  modification49. In brief, 
a flat microtiterplate containing the bacterial suspension was held in a plastic holder tight to the bottom of a 
closed dark chamber of an ultrasonic bath containing cooled distilled water. This was done to prevent any exter-
nal illumination. Sonication was conducted at a frequency of 1 MHz and pulsed repetition frequency of 100 Hz 
with a spatial average ultrasonic intensity of 2 W/cm2 for 5 min. An ultrasound transducer with a surface area 
of 7.0  cm2 was applied at the bottom of the chamber of the ultrasonic bath to provide exposure to the bacterial 
suspension.
Experimental design. To determine the antimicrobial response to Cur-NPhs-mediated PSACT, test 
groups consisted of A. actinomycetemcomitans subjected to:
 1. NPhs: at the concentrations of 10, 25, and 50 ×  10–4 g/L.
 2. Cur-NPhs: at the concentrations of 10, 25, and 50 ×  10–4 g/L.
 3. Blue laser: irradiation at a wavelength of 450 ± 5 nm for 2 min.
 4. Ultrasonic waves: the intensity of 2 W/cm2 for 2 min at a frequency of 1 MHz.
 5. NPhs-aPDT: NPhs (10, 25, and 50 ×  10–4 g/L) + blue laser irradiation at a wavelength of 450 ± 5 nm for 
2 min.
 6. Cur-NPhs-aPDT: Cur-NPhs (10, 25, and 50 ×  10–4 g/L) + blue laser irradiation at a wavelength of 450 ± 5 nm 
for 2 min.
 7. NPhs-SACT: NPhs (10, 25, and 50 ×  10–4 g/L) + ultrasonic waves with the intensity of 1.56 W/cm2 for 2 min 
at a frequency of 1 MHz.
 8. Cur-NPhs-SACT: Cur-NPhs (10, 25, and 50 ×  10–4 g/L) + ultrasonic waves with intensity of 1.56 W/cm2 
for 2 min at a frequency of 1 MHz.
 9. NPhs-PSACT: NPhs (10, 25, and 50 ×  10–4 g/L) + blue laser irradiation at a wavelength of 450 ± 5 nm + ultra-
sonic waves with the intensity of 1.56 W/cm2 at a frequency of 1 MHz for 2 min.
 10. Cur-NPhs-PSACT: Cur-NPhs (10, 25, and 50 ×  10–4 g/L) + blue laser irradiation at a wavelength of 
450 ± 5 nm + ultrasonic waves with the intensity of 1.56 W/cm2 at a frequency of 1 MHz for 2 min.
 11. Control group (bacterial suspension without treatment).
aPDT protocol. To find out the effect of aPDT based on NPhs and Cur-NPhs at different concentrations (10, 
25, and 50 ×  10–4 g/L; final concentration), 100 μL of each concentration of test materials was added to the well of 
a 96-well microtiterplate. The wells were then inoculated with a 100 μL/well of fresh BHI broth bacterial cultures 
(adjusted to the final concentration of 5.0 ×  105 CFU/mL). The microtiterplate was incubated for 5 min in the 
dark at 25 °C. The NPhs and Cur-NPhs treated bacterial suspensions in microtiterplate wells were immediately 
exposed with the blue laser irradiation at a wavelength of 450 ± 5 nm for 2 min.
EE% =
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SACT protocol. SACT was performed as described  previously50. Briefly, 100  μL of NPhs and Cur-NPhs 
at different concentrations (10, 25, and 50 ×  10–4 g/L; final concentration) separately was added to the well of a 
96-well microtiterplate. The wells were then inoculated with a fresh BHI broth bacterial suspension (100 μL/well; 
final concentration of 5.0 ×  105 CFU/mL). The microtiterplate was incubated in the dark room (5 min; 25 °C). 
After that sonication was done with an ultrasound transducer containing a surface area of 7.0  cm2 at a pulsed 
repetition frequency of 100 Hz.
PSACT protocol. 100 μL of bacterial suspension (1.5 ×  106 CFU/mL) was transferred to the wells of the 
96-well microtiterplate. 100 μL of NPhs and Cur-NPhs at different concentrations (10, 25, and 50 ×  10–4 g/L) 
were separately added to the bacterial suspension. After incubation of the microtiter plate in a dark capnophilic 
atmosphere for 5 min at room temperature, the bacterial suspension was simultaneously exposed to blue laser 
at the wavelength of 450 ± 5 nm with an output intensity of 150 mW/cm2 and ultrasonic waves at a frequency 
of 1 MHz with an ultrasonic intensity of 2 W/cm2 for two min. The schematic diagram of PSACT is shown in 
Fig. 11.
Determination of viability of A. actinomycetemcomitans in planktonic culture following treat‑
ment groups. 100 μL of NPhs and Cur-NPhs (both at the concentrations of 200 ×  10–4 g/L) were added to 
the well in column one of a 96-well microtiterplate, separately, and was diluted two-fold stepwise to column 
three after adding 100 μL of 2 × BHI broth to each well. Then, an A. actinomycetemcomitans suspension (100 μL 
of 1.5 ×  106 CFU/mL) was poured into each well. In this experiment, the concentration of test materials was in 
the range of 10, 25, and 50 ×  10–4 g/L. Then microtiterplate was incubated for 24 h under capnophilic condition, 
in the dark, at 37 °C. Thereafter, 50 μL of each well were cultured in a BHI agar plate supplemented with 0.6% 
(wt/vol) yeast extract, 5–7% defibrinated sheep blood, 5 mg/L hemin, and 1 mg/L menadione. The BHI agar 
plates were incubated in a capnophilic condition at 37 °C for 48 h, and the number of CFU/mL was determined.
The effect of NPhs- and Cur-NPhs-mediated aPDT-, SACT-, and PSACT-treatment on A. actinomycetem‑
comitans in planktonic culture were done according to the method mentioned as  previously42. Briefly, NPhs 
and Cur-NPhs (both 100 μL; 200 ×  10–4 g/L) were added to the well in column one of a 96-well microtiterplate, 
separately, and was diluted two-fold stepwise to column three after adding of 2 × BHI broth (100 μL) to each 
well. Then, an A. actinomycetemcomitans suspension (100 μL of 1.5 ×  106 CFU/mL) was added into each well. 
The microtiterplate was incubated for 5 min in the dark, at 25 °C. The contents of microtiterplate wells were 
immediately treated in aPDT-, SACT-, and PSACT-protocols as mentioned in the experimental design section. 
As mentioned in the above paragraph, the number of CFU/mL of treated A. actinomycetemcomitans in planktonic 
culture was determined.
Determination of treatment groups efficiency on biofilm killing/degradation. The biofilm kill-
ing/ degradation effect of NPhs- and Cur-NPhs-mediated aPDT-, SACT-, and PSACT-treatment was deter-
mined according to a previous  study51. Briefly, aliquots in BHI broth medium of bacterial suspensions (200 µL; 
1.0 ×  105 CFU/mL final concentration) were transferred into each well in 96-well microtiterplate. To maturation 
biofilm of A. actinomycetemcomitans then microtiterplate was incubated for 48 h in capnophilic condition, at 
37 °C. After that, the medium was removed from each well, and planktonic cells were deducted by washing three 
Figure 11.  Schematic apparatus for illumination treatment of sample.
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times with PBS (pH 7.4). A. actinomycetemcomitans cells in biofilms were treated in aPDT-, SACT-, and PSACT-
protocols as mentioned in the experimental design section.
After each treatment, biofilm killing/degradation was assessed with the colorimetric method based on CV 
 assay52. The content of each well of microplates was removed and the planktonic cells were deducted were allowed 
to air dry at room temperature. Then, the wells were stained with CV dye (1%) for 20 min at 25 °C, and the dye 
was discarded and washed twice with PBS (pH 7.4). Ethanol (200 μL; 95%) was added into each well and was 
incubated for 15 min at 25 °C. Then, the content of each well quite was aspirated and the microtiterplate was 
allowed to air dry at room temperature. Thereafter, each well was filled with acetic acid (200 μL; 33%) and biofilms 
were quantified by measuring the optical densities (OD) value using a microplate reader machine (at 570 nm; 
Thermo Fisher Scientific, US). To assess the treatment efficiency of NPhs- and Cur-NPhs-mediated aPDT-, 
SACT-, and PSACT-efficiency on biofilm killing/degradation, the percentage of biofilm killing/degradation was 
determined by the following equation:
Assessment of metabolic activity of treatment groups using XTT reduction assay. The meta-
bolic activity of treated A. actinomycetemcomitans was assessed using the XTT (2,3-bis [2-methyloxy-4-nitro-
5-sulfophenyl]-2H-tetrazolium-5-carboxanilide) reduction assay, as described by Coraça-Hubér et  al.53. Fol-
lowing each treatment described in the experimental design section, the content of wells was collected and 
centrifuged at 2000 rpm for 10 min. The supernatants were removed and resulting bacterial cell sediments were 
dissolved in 150 μL of XTT-menadione-PBS solution in microplate wells and incubated at 37  °C. After 3 h, 
100 μL of the mixture was transferred to a new microplate and the optical intensity was measured at 492 nm 
using a microplate reader.
Determination of relative quantification of quorum‑sensing‑associated qseB and qseC genes 
expression. To determine the effects of treatment groups on QS genes expression in A. actinomycetemcomi‑
tans, the treated A. actinomycetemcomitans was used to extract RNA using GeneAll Hybrid-R RNA purification 
kit following the manufacturer’s instructions. The extracted RNA was quantified spectrophotometrically using 
a NanoDrop spectrophotometer Thermo Fisher Scientific, US) and the quality was confirmed on the agarose 
gel. Total RNA was pretreated with RNase-free DNase I treatment according to the manufacturer’s protocol to 
remove any residual chromosomal DNA. The first-strand cDNA was synthesized from the total RNA using a 
Revert Aid First Strand cDNA Synthesis Kit according to the manufacturer’s protocol. Quantitative real-time 
polymerase chain reaction (qRT-PCR) was then performed to quantify gene transcription of qseB and qseC. The 
nucleotide sequences of primers used in this study were shown in Table 1. The specificity of the primers was 
evaluated on agarose gel electrophoresis. Reaction plates were processed on the Line-GeneK Real-Time PCR 
Detection System and Software (Bioer Technology, Hangzhou, China) using SYBR Green master mixes with the 
following cycling parameters: initial denaturation at 95 °C/2 min, followed by 40 cycles at 94 °C/10 s, 60 °C/10 s, 
and 72 °C/10 s. Finally, the expression level of qseB and qseC genes was analyzed based on the previous  study54. 
16S rRNA was used as an internal control to normalize RNA concentration.
Determination of relative quantification of biofilm‑associated rcpA gene expression. The 
evaluation of rcpA expression was performed based on the previous  study42. Total RNA extraction, cDNA syn-
thesis, and qRT-PCR was done as described above (Section Determination of relative quantification of quorum-
sensing-associated qseB and qseC genes expression).
Statistical analyses. All experiments were performed in triplicate and expressed as mean ± standard devi-
ation (SD). All quantitative data were analyzed with one-way analysis of variance (ANOVA) and Tukey test using 
the SPSS software version 23.0. The significance level was set at P < 0.05. Fold differences in RNA expression were 
determined by the  2−ΔΔCt method and the changes greater than or equal to two-fold were considered  significant54.
Biofilm killing/degradation% =
OD of untreated A. actinomycetemcomitans − OD of sample
OD of untreated A. actinomycetemcomitans
×100
Table 1.  Primer sequences used in this study.
Gene Primer Sequence (5′→3′) Length Size (bp)
qseB
Forward GCA GTG GTG CTG GAT TTA ACC TTG 24
157
Reverse GCG TTA CTG CTC ACT TCG TTA TCC C 25
qseC
Forward TAA GTG GAA TAA TTA CAG CCT GCG 24
176
Reverse TTG TTG TGC GTC AAA CAC TTG GTT C 25
rcpA
Forward GGG CAT TAA CTG GAG CCA C 19
72
Reverse ATC CAC CTC CGA AAC CGA AG 20
16S rRNA
Forward GTG AAA TCC CCG GGC TTA AC 20
217
Reverse ACC GTT TAC AGC GTG GAC TA 20
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